Gene Expression Profile of T-cell Receptors in the Synovium, Peripheral Blood, and Thymus during the Initial Phase of Collagen-induced Arthritis

Ji-Young Kim1, Mi Kyoung Lim1, Dong Hyuk Sheen1, Chan Kim2, So Young Lee1, Hyo Park1, Min Ji Lee1, Sang Kwang Lee1, Yun Sik Yang3 and Seung Cheol Shim1*

1Department of Medicine, Eulji Medi-Bio Research Institute, 2Department of Physiology, School of Medicine, Eulji University, Daejeon 302-799, 3Genome Research Center for Immune Disorders, School of Medicine, Wonkwang University, Iksan 570-749, Korea

Background: Current management strategies attempt to diagnose rheumatoid arthritis (RA) at an early stage. Transcription profiling is applied in the search for biomarkers for detecting early-stage disease. Even though gene profiling has been reported using several animal models of RA, most studies were performed after the development of active arthritis, and conducted only on the peripheral blood and joint. Therefore, we investigated gene expression during the initial phase of collagen-induced arthritis (CIA) before the arthritic features developed in the thymus in addition to the peripheral blood and joint.

Methods: For gene expression analysis using cDNA microarray technology, samples of thymus, blood, and synovium were collected from CIA, rats immunized only with type II collagen (CII), rats immunized only with adjuvant, and unimmunized rats on days 4 and 9 after the first immunization. Arrays were scanned with an Illumina bead array.

Results: Of the 21,910 genes in the array, 1,243 genes were differentially expressed at least 2-fold change in various organs of CIA compared to controls. Among the 1,243 genes, 8 encode T-cell receptors (TCRs), including CD3ζ, CD3δ, CD3ε, CD8α, and CD8β genes, which were down-regulated in CIA. The synovium was the organ in which the genes were differentially expressed between CIA and control group, and no difference were found in the thymus and blood.

Conclusion: This study provides evidence that the genes encoding TCRs including CD3ζ, CD3δ, CD3ε, CD8α, and CD8β genes were down-regulated during the initial phase of CIA in the synovium of CIA. In addition, adjuvant played a greater role in the down-regulation of the CD3 complex compared to CII. Therefore, the down-regulation of TCR gene expression occurred dominantly by adjuvant could be involved in the pathogenesis of the early stage at CIA.

INTRODUCTION

Rheumatoid arthritis (RA) is characterized by a chronic inflammatory process, which primarily involves the synovial membrane and is typically associated with serologic evidence of systemic autoimmunity, culminating in loss of joint function (1). The presence of auto-antibodies, such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, can precede the clinical manifestations of RA by many years (2). Therefore, it is recommended that effective therapy be initiated as soon as autoimmune abnormalities appear (3); however, there are many unanswered questions regarding the pre-clinical stages of RA. The central questions relate to the factors that serve to initiate, amplify, and mature the immune responses in RA. It is difficult to investigate the molecular features in patients with RA before the onset of clinical symptoms, which is possible in animal models.
Collagen-induced arthritis (CIA) has been used to study the basic mechanisms of autoimmune arthritis because of the clinical, immunologic, histologic, and genetic similarity to RA (4-6). In this model, native type-II collagen (CII), when presented with an adjuvant, predictably and reproducibly precipitates a chronic inflammatory arthritis in the joints of genetically-susceptible animals. The development of CIA is thought to depend on T cells, and disease susceptibility is linked to the major histocompatibility complex (MHC) (7). CII-specific CD4+ T cells have been reported to be fundamental in the initiation and perpetuation of CIA (8,9). Recently, abatacept, which targets T-cell modulation via the co-stimulatory CD80/CD86:CD28 pathway, exemplifies the rationale and efficacy of using T-cell modulation as a therapeutic approach (10). Therefore, the abnormality in T cell-related immunity plays a role in the pathogenesis of RA. In addition, the primary mechanism leading to tolerance to self-antigens is the deletion of self-reactive T cells in the thymus through the mechanism by which T cells with a high affinity for self-peptides undergo the active induction of apoptosis. Autoimmune arthritis in various animal models can be attributed to a defect in T cell selection within the thymus (11-13). Since, we questioned where and when T cell immunity dysregulation occurs, we investigated the gene expression of T cell-related molecules, in the thymus, peripheral blood and synovium during the initiation phase of CIA using cDNA microarray technology followed by validation using real-time PCR.

MATERIALS AND METHODS

Animals
Adult female Lewis rats (7 weeks old) weighing approximately 150 g were obtained from Harlan (Indianapolis, IN, USA), housed under standard conditions, and given free access to food and water. The rats were adapted to the new conditions for at least 7 days before the initiation of the studies. All experiments were conducted in accordance with the animal care guidelines of the National Institutes of Health and the Korean Academy of Medical Sciences. This study was approved by the Eulji University Animal Institutional Review Board.

Rat CIA model
Chicken CII (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.05 M acetic acid to a final concentration of 4 mg/ml, CII emulsified in incomplete Freund’s adjuvant (IFA) was homogenized at a 1:1 ratio using a PowerGen 35 (Fisher Scientific, Pittsburgh, PA, USA). For the induction of CIA, rats, 8 weeks old (n=3 per group), were immunized intradermally at the base of the tail with 0.2 ml of the emulsion on day 0, followed by one-half volume of each on day 7. Another group of rats were immunized only with and equivalent volume of IFA, only with CII on the same days. Non-immunized rats were used of control group.

Arthritis was assessed daily, and inflammation was scored, as described by Nanakumar and co-workers (14). In our previous study, the induction ratio of CIA was >86%.

Each experimental condition was reproduced three times (RNA isolation, probe preparation, and independent hybridization), and each replicate contained RNA samples pooled from three animals.

For gene expression analysis, the sample was collected on days 0 (control), 4, and 9. Sample tissues from three rats were collected at each time point. Blood was collected through the postcaval vein from each animal. Synovium was collected from the posterior knee joint. Samples were treated with RNAlater (Ambion, Austin, TX, USA) to prevent RNA degradation.

RNA preparation
Total RNA was extracted using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA) and purified using RNeasy columns (Qiagen, Valencia, CA, USA), according to the manufacturer’s protocol. After processing with DNase digestion and clean-up procedures, the RNA samples were quantified, aliquotted, and stored at −80°C until use. For quality control, RNA purity and integrity were evaluated by denaturing gel electrophoresis, the OD 260/280 ratio, and analyzed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).

Labeling and purification
Total RNA was amplified and purified using the Ambion Illumina RNA amplification kit (Ambion) to yield biotinylated cRNA, according to the manufacturer’s instructions. Briefly, 550 ng of total RNA was reverse-transcribed to cDNA using a T7 oligo (dT) primer. Second-strand cDNA was synthesized, in vitro-transcribed, and labeled with biotin-NTP. After purification, the cRNA was quantified using a ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA).
Hybridization and data export

Seven hundred fifty nanograms of labeled cRNA samples were hybridized to each Rat-12 expression bead array for 16 ~ 18 h at 58°C, according to the manufacturer's instructions (Illumina Inc., San Diego, CA, USA). Detection of array signals was carried out using Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK), according to the bead array manual. Arrays were scanned with an Illumina bead array Reader confocal scanner, according to the manufacturer's instructions. Array data export processing and analysis was performed using Illumina BeadStudio.

Raw data preparation and statistical analysis

The quality of hybridization and overall chip performance were monitored by visual inspection of internal quality control checks and the raw scanned data. Raw data were extracted using the software provided by the manufacturer (BeadStudio v. 3, 3, 0). Array data were filtered by a detection p-value < 0.05 (similar to signal-to-noise) in at least 50% of the samples. We applied a filtering criterion for data analysis; a higher signal value was required to obtain a detection p-value < 0.05. The selected gene signal value was transformed by logarithm and normalized by the quantile method. Comparative analyses were carried out using a |Fold| > 2. Hierarchical cluster analysis was performed using complete linkage and Euclidean distance as a measure of similarity. All data analyses and visualization of differentially-expressed genes were conducted using ArrayAssist® (Stratagene, La Jolla, CA, USA). Ontology-based analyses were performed using the Panther database (http://www.pantherdb.org).

Reverse transcription and real-time PCR

Reverse transcription (RT) was carried out according to the instructions in the ImProm-II™ reverse transcription system (Promega, Madison, WI, USA). In brief, 1 μg of total RNA was reverse-transcribed in a total volume of 20 μl using an oligo-dT primer. The RT reaction was performed at 25°C for 5 min, 42°C for 1 hr, and 70°C for 15 min. One μl of cDNA was used as a template for real-time PCR in a 25 μl reaction mixture, including 0.75 U of GoTaq DNA polymerase (Promega), 5 μl of 5X buffer, 0.2 mm of dNTP (Promega), 2.5 μl of 3000X SYBR Green 1 (BMA, Rockland, ME, USA), and 10 pM of each primer. Oligonucleotide primers for real-time PCR were prepared using Primer 3 software (Whitehead Institute/MIT Center for Genomes Research, Cambridge, MA: http://www.bioneer.co.kr/cgi-bin/primer/primer3.cgi). Information and sequences of primers of the steroidogenic enzymes tested in the present study are summarized in Table I. The PCR program used an initial step of 95°C for 5 min for pre-denaturation, followed by denaturation at 94°C, annealing, and extension at 72°C using the PTC-200 Chromo 4 real-time system (Bio-Rad Laboratories, Hercules, CA, USA). The final extension was carried out for 10 min at 72°C. Beta-actin was included as an internal PCR control. For quantification of real-time PCR results, the relative standard curve method was used to obtain quantitative values. Each sample was replicated three-to-four times, and the normalized mean value to beta-actin was used for final comparison.

Real-time PCR data presentation and statistical analysis

Data for mRNA abundance were expressed relative to the control and CIA groups on days 4 and 9. In the figures, data are presented as the mean±standard error. Comparisons between CIA and controls were performed using one-way analysis of variance, followed by the Mann-Whitney U test, using SPSS software (SPSS Inc., Chicago, IL, USA). In all cases, a p < 0.05 was considered statistically significant.

Histology

At the end of each experiment, the knee joints were fixed in 4% formalin for 2 days, decalcified in EDTA for 3 weeks, then embedded in paraffin. From the paraffin-embedded tis-

Table I. Primer sequences used in real-time PCR

| Gene | Forward | Reverse |
|------|---------|---------|
| CD8 α | 5'-GGCCAGGAGGTGAAGCTAAC-3' | 5'-GCTAGGCTTGCTAAGGGTGA-3' |
| CD8 β | 5'-CATGGATGTGAAGCCAGAGG-3' | 5'-ATGAAGTGAATCCGGGCTCT-3' |
| CD3 δ | 5'-GTCGCCAAGAACTGTGGAGC-3' | 5'-TGGCCTGCAAAGCAGTAGAC-3' |
| CD3 ε | 5'-ATGCAGTGGAACGCTTTCTG-3' | 5'-GAGGGCACGTCAGCTCTACG-3' |
| CD3 ζ | 5'-GCTGCTTACCTTCAGGACCC-3' | 5'-GCTGAGACCCTGGTAAAGGC-3' |
sue blocks, 2-μm sections were cut and stained with haematoxylin-eosin for histologic analysis.

RESULTS

A great number of genes were significantly modulated during the initiation stage of CIA
To define the gene expression profile in the initiation stages of CIA, we used an expression chip with 21,910 gene specificities. First, gene expression was compared between the CIA and control groups on days 4 and 9 after the 1st immunization. We observed 1,243 genes were expressed differentially in CIA on day 4 than on day 9, which could be attributable to a biological process or molecular function (Fig. 1). Table II shows the list of up- or down-regulated genes according to the organ in which they were differentially-expressed. We found that the synovium was the organ in which most genes were differentially-expressed, and only one gene, Il1f8, was differentially-expressed in the blood. No gene was differentially-expressed in the thymus.

Differential expression of genes encoding T-cell receptors (TCRs) in arthritic synovial tissue of CIA
Since we founded on T cell associated genes, we analyzed genes related to TCR/CD3 complex, including CD3$\delta$, CD3$\varepsilon$, CD3$\zeta$, and CD3$\xi$. Interestingly, most genes encoding TCR were down-regulated in CIA (Fig. 2A). Day 4 showed a greater difference in gene expression than day 9 between CIA and controls. Next, we analyzed which organ showed differentially expressed genes, The synovium was the only organ in which the genes were differentially expressed between CIA and control groups, whereas no difference was found in the thymus and blood.

Next, we analyzed gene expressions of CD4 and CD8 which are another T cell surface molecules that play an additional role in T cell recognition (15). The expression of the CD8$\alpha$ and CD8$\beta$ genes were reduced significantly in CIA, however the CD4 gene was expressed similarly between CIA and control groups (Fig. 2B). To validate our microarray findings, we performed real-time RT-PCR on the genes of TCR/CD3 and T cell co-receptors using independent animals. The expression of CD3$\delta$, CD3$\varepsilon$, CD3$\zeta$, CD3$\xi$, CD8$\alpha$, and CD8$\beta$, as revealed by RT-PCR, was in agreement with the microarray data (Fig. 3).

Gene expression profile in rats immunized only with CII or adjuvant
We next determined whether the differential expression of T cell-mediated genes was more affected by CII or adjuvant. We compared four groups of rats, including rats immunized both with IFA and CII (CIA), rats immunized only with IFA (rIFA), rats immunized only with CII (rCII), and unimmunized rats. As shown in the previous analysis between the CIA and control groups, gene expression profile showed greater difference on day 4 than day 9 both in rCII and rIFA (Fig. 4).

Table II. List of immune-mediated genes that were up- or down-regulated in each organ of CIA compared to control groups

| Gene   | Thymus 4 days | Blood 4 days | Synovium 4 days | Thymus 9 days | Blood 9 days | Synovium 9 days |
|--------|---------------|--------------|-----------------|---------------|--------------|-----------------|
| Itk    | 1.00          | -1.37        | -7.56           | 1.01          | -1.37        | -2.68           |
| Il1f8  | 1.09          | 2.11         | 1.34            | 1.09          | 2.11         | 1.34            |
| CD3$\delta$ | -1.16       | -1.14        | -1.28           | -1.16         | -1.14        | -1.28           |
| CD6    | -1.16         | -1.03        | -1.08           | -1.06         | -1.04        | -1.13           |
| CD3$\varepsilon$ | 1.06        | 1.04         | -1.11           | 1.06          | 1.04         | -1.11           |
| CD3$\xi$ | -1.02         | 1.10         | -1.05           | -1.02         | 1.10         | -1.05           |
| CD8$\beta$ | 1.08         | 1.09         | -1.05           | -1.08         | 1.09         | -1.05           |
| CD8$\alpha$ | -1.09        | -1.15        | -1.18           | -1.09         | -1.15        | -1.18           |

The data shown here are the ratio of gene expression of the CIA-to-control group in each organ.
Figure 2. The ratio of TCR-related gene expression of the CIA-to-control group in each organ in the initiation phase of CIA. TCR-related gene expression was compared between the CIA and control groups. The data shown here are the ratio of gene expression of the CIA-to-control group in each organ. (A) CD3 complex gene expression. CD3δ, CD3ε, and CD3ζ gene expression was down-regulated in the synovium of CIA, with no differences in the thymus and blood. (B) CD4 and CD8 gene expression. CD8α and CD8β gene expression was down-regulated in the synovium of CIA, with no difference in the thymus and blood. No difference in CD4 gene expression existed between the CIA and control groups in the synovium, thymus, or blood.

Figure 3. Validation of the CD3 complex and CD8 gene expression in CIA and control groups. RT-PCR was performed using SYBR and a specific primer set for (A) CD3δ, (B) CD3ε, (C) CD3ζ, (D) CD8α, and (E) CD8β. The RNA samples are independent of the samples used for microarray analysis. Data are expressed as the mean±SD. *p<0.05 by the Mann-Whitney U test.
Figure 4. Number of genes differentially-expressed in CIA and rats immunized only with CII or adjuvant. To define the gene expression profile in the initiation stages of CIA, we used a RatRef-12 expression beadchip (Illumina Inc., San Diego, CA, USA) with 21,910 gene specificities, and compared the following 3 groups of rats with the control group: (A) IFA/CII immunized (CIA), (B) CII immunized, and (C) IFA (MDP). Samples were collected from the thymus (black bar), blood (white bar), and synovium (dotted bar).

Table III. List of TCR-mediated genes that were up- or down-regulated in the synovium of CIA compared to control depending on various inducers

| Gene | Fold change (treatment/control) |
|------|--------------------------------|
|      | CIA | IFA | CIA |
|      | 4 day | 9 day | 4 day | 9 day | 4 day | 9 day |
| CD3 δ | -1.89 | 1.53 | −21.84 | -3.19 | -14.84 | -5.48 |
| CD3 ε | -3.17 | -1.35 | -6.03 | -1.86 | -7.68 | -2.77 |
| CD3 ζ | -1.61 | 1.20 | -10.59 | -2.59 | -9.46 | -3.72 |
| CD4 | -4.13 | -1.46 | -2.44 | -1.88 | -1.63 | 1.02 |
| CD8 α | -2.46 | -1.09 | -21.48 | -4.03 | -11.96 | -4.59 |
| CD8 β | -2.31 | -1.06 | -9.73 | -2.92 | -7.60 | -2.93 |

The data shown here are the ratio of gene expression of the immunized rat-to-control group in each organ.

CIA: collagen induced arthritis, CII: native type-II collagen, IFA: incomplete Freund adjuvant.

Most genes were differentially expressed in the synovium, whereas the thymus showed only one gene differentially-expressed in rCII on day 9.

Interestingly, the synovium of CII showed down-regulation of one CD3 complex gene, CD3 ε, whereas the synovium of IFA showed down-regulation of more genes including CD3 δ, CD3 ε, and CD3 ζ on day 4, as shown in CIA (Table III). Furthermore, the difference of gene expression compared to controls was greater in rIFA than in CIA. In terms of T cell co-receptor, even though both the synovium of rCII and rIFA showed down-regulation of CD8 α and CD8 β, a greater difference in gene expression was shown in rIFA compared to rCII or CIA. CD4 gene expression was decreased in rIFA compared to rCII, which was not shown in CIA.

In addition, other genes were expressed differentially on rCII or rIFA, which was not differentially expressed in CIA. The blood of rCII revealed up-regulation of Btk, Tmro, and Taphc on day 4, and up-regulation of Il1r and G)

The blood of rIFA showed up-regulation of Sqtms1 and down-regulation of Taphc, Hla-dma, and Nfatc3 (Table IV).

The blood of rIFA showed up-regulation of Il1f8, Adora2a, Tnfrsf1a, and Ifi35, in addition to that showed the genes that showed increased expression in rCII on day 4. The Sh2d2a, Cse, Gzmk, and Itk were down regulated in the blood of rIFA, and the synovium of rIFA showed down-regulation of Sh2d2a, Cse, Nfatc3, Slr, and Itk on day 4 (Table V).

Pathologic analysis of synovium in CIA rats and controls

We also examined synovia pathologically at the initiation time, but there were no differences among the four groups, including CIA, rIFA, rCII, and unimmunized. These results indicated that there were changes at the molecular level before histologic changes began, including synovial hypertrophy, pannus formation, cartilage destruction, and bone erosion.
DISCUSSION

During the 1990s, the widely accepted concept of cytokine networks perpetuating disease, with tumor necrosis factor (TNF-α) assuming a hierarchical role (16), was supported by the success of TNF-α-blocking treatment in RA (17,18). However, the lack of universal benefit from TNF-α-blocking therapy (19) has focused attention to alternative upstream immunologic mediators. The central questions relate to the factors that serve to initiate, amplify, and mature the immune responses in RA. Gene expression profiles at different stages of CIA have been reported previously (20). However, it is difficult to determine the causal genes in those studies because too many genes were already expressed when investigated focused on T cell immunity-related genes because several observations over the years supported a fundamental role for T cells in RA (21,22). RA synovium contains a rich infiltrate of activated CD4+ cells and MHC class II molecules (23) with a correlation between the number of synovial T cells and the severity of joint damage (24).

Our original hypothesis was that T cells could escape negative selection because intracellular signal transduction of thymocytes was dysregulated. The TCR/CD3 complex is one of the most intricate membrane receptor structures because it consists of six distinct chains (26,27). The clonotypic α and β chains of the TCR are responsible for recognizing antigen embedded in the MHC molecule present on the surface of

Table IV. List of immune-mediated genes that were up- or down-regulated in each organ of rats immunized only with CII compared to control groups

| Gene       | Thymus | Blood | Synovium |
|------------|--------|-------|----------|
|            | Day 4  | Day 9 | Day 4    | Day 9   | Day 4 | Day 9 |
| Btk        | 1.21   | 1.21  | 2.06     | 1.29    | 1.64  | 1.66  |
| Tmpr       | 1.17   | 1.77  | 2.25     | 1.98    | 1.47  | 1.17  |
| Tapbp      | 1.13   | 1.05  | 2.49     | 1.18    | 2.39  | 1.09  |
| CD3 δ      | 1.05   | 1.04  | -2.26    | 1.05    | -1.89 | 1.53  |
| Sqstm2     | 1.00   | -1.02 | 1.08     | 1.21    | 2.11  | 1.04  |
| Sqstm1     | 1.20   | -1.19 | 1.78     | 1.30    | 2.40  | 1.15  |
| Hla-dma    | 1.04   | -1.43 | -1.09    | -1.50   | -3.05 | -1.33 |
| CD4        | 1.14   | 1.33  | 1.19     | -1.12   | -4.13 | -1.46 |
| CD8 β      | 1.23   | -1.16 | -1.05    | 1.52    | -2.31 | -1.06 |
| CD3 ε      | 1.15   | 1.05  | 1.11     | 1.25    | -3.17 | -1.35 |
| CD8 γ      | -1.30  | -1.08 | -1.46    | 1.03    | -2.46 | -1.09 |
| Il9r       | 1.46   | 1.55  | 1.38     | 2.14    | 1.17  | 1.13  |
| Cts       | -1.63  | 2.15  | -1.16    | -2.25   | 1.08  | 1.52  |
| Ciita      | 1.15   | 1.15  | 1.69     | 2.19    | 1.23  | 1.24  |
| Sh2d2a     | -1.12  | -1.28 | -1.49    | -2.04   | -1.33 | -1.04 |

The data shown here are the ratio of gene expression of the immunized rat-to-control group in each organ.

Table V. List of immune-mediated genes that were up- or down-regulated in each organ of rats immunized only with adjuvant compared to control groups

| Gene       | Thymus | Blood | Synovium |
|------------|--------|-------|----------|
|            | Day 4  | Day 9 | Day 4    | Day 9   | Day 4 | Day 9 |
| Il1f8      | 1.42   | 1.00  | 2.87     | 2.21    | -1.01 | 1.02  |
| Adora2a    | 1.55   | 1.27  | 2.49     | 2.05    | 1.35  | 1.51  |
| Btk        | -1.03  | -1.36 | 2.20     | -1.02   | -1.62 | 1.46  |
| Tnfrsf1a   | -1.17  | 1.16  | 2.70     | 2.20    | 1.14  | 1.43  |
| Tmpr       | 1.25   | 1.29  | 2.30     | 1.98    | 1.02  | 1.24  |
| Tapbp      | -1.20  | -1.08 | 2.16     | -1.07   | -1.12 | 1.13  |
| If35       | -1.13  | -1.03 | 2.26     | 1.94    | 1.02  | 1.05  |
| Sqstm1     | 1.23   | 1.42  | 2.00     | 1.04    | 1.60  | 1.30  |
| Sh2d2a     | -1.19  | -1.02 | -2.35    | -2.25   | -2.15 | -1.34 |
| Ctse       | -1.27  | 1.00  | -2.04    | 1.73    | -2.61 | -1.74 |
| CD8 α      | -1.38  | -1.24 | -2.20    | -1.24   | -21.48| -4.03 |
| CD3 δ      | 1.03   | 1.11  | -2.21    | -1.31   | -21.84| -3.19 |
| Itk        | -1.05  | 1.33  | -2.70    | -2.16   | -9.22 | -2.26 |
| Gzmk       | -1.09  | 1.07  | -3.25    | 1.53    | -1.01 | 1.00  |
| CD3 ε      | -1.00  | 1.08  | -2.21    | -1.39   | -10.59| -2.59 |
| Nfatc3     | 1.02   | 1.09  | -1.82    | -1.30   | -3.04 | -1.42 |
| CD4        | -1.05  | 1.15  | 1.58     | 1.63    | -2.44 | -1.88 |
| Sla        | 1.28   | 1.32  | -1.01    | 1.11    | -2.01 | -1.46 |
| CD8 β      | 1.07   | 1.03  | -1.04    | 1.45    | -9.73 | -2.92 |
| CD3 ε      | 1.09   | 1.11  | -1.41    | -1.23   | -6.03 | -1.86 |

The data shown here are the ratio of gene expression of the immunized rat-to-control group in each organ.
antigen-presenting cells (APCs). The remaining chains, collectively called the CD3 complex, include the CD3-γ, -δ, -ε, and -ζ chains (26). T cells implicated in chronic inflammatory diseases, such as RA, respond weakly when stimulated in vitro with mitogen or antigen (28). Decreased expression of the TCR-associated CD3ζ chain has been suggested, but the mechanism underlying this hypo-responsiveness is unclear (29-33). Therefore, we investigated when TCR started to be decreased in the course of CIA development.

We focused on the initiation time before looking at the whole picture through the total period of CIA development.

In our study, TCR down-regulation occurred at an early phase of CIA, and most genes expressed differentially were found in the synovium, not in the thymus and blood. Synovium tissue contains heterogeneous population of stromal cells and immune cells. Especially, there was definitely higher number of lymphocyte infiltrated in the synovium of CIA rats compared to the control group. Therefore, infectious triggers might play an important role in the down-regulation of the TCR gene CIA.

Furthermore, more genes were shown to be expressed differentially when we immunized rats with CII or adjuvant compared to the CIA. Even the blood in the rats immunized with CII only and with adjuvant only revealed another genes which were expressed differentially, including Btk, Tmpo, Tnfrsf1a, Il15r, Cd40, Nfatc3, Adora2a, Sqstm1, Tgps, Gzmk, and Itk.

The function of those genes in the pathogenesis of CIA remains to be elucidated.

ACKNOWLEDGEMENTS

This work was supported by a grant from the Korea Health 21 R&D Project by Ministry of Health & Welfare (01-PJ3-PG6-01GN09-003).

CONFLICTS OF INTEREST

The author have no financial conflict of interest.

REFERENCES

1. Firestein GS, Zvaifler NJ. Rheumatoid Arthritis: A Disease of Disordered Immunity. New York: Raven Press; 1992.
2. Aho K, Heilövaara M, Maatela J, Tuomi T, Palosuo T: Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 18:1262-1264, 1991.
3. Cush JJ: Early rheumatoid arthritis - is there a window of opportunity? J Rheumatol (Suppl) 80:1-7, 2007.
4. Durie FH, Fava RA, Noelle RJ: Collagen-induced arthritis as a model of rheumatoid arthritis, Clin Immunol Immunopathol 73:11-18, 1994.
5. Brunsberg U, Gustafsson K, Jansson L, Michaëllsson E, Ahlund-Richter L, Peterson S, Mattsson R, Holmdahl R: Expression of a transgenic class II Ab gene confers suscept-
ability to collagen-induced arthritis, Eur J Immunol 24:1698-1702, 1994.
6. Stuart JM, Townes AS, Kang AH: Nature and specificity of
the immune response to collagen in type II collagen-in-
duced arthritis in mice. J Clin Invest 69:573-585, 1982.
7. Wooley PH, Luftsa HS, Stuart JM, David CS: Type II colla-
gen-induced arthritis in mice. I. Major histocompatibility
complex (I region) linkage and antibody correlates. J Exp
Med 154:698-700, 1981.
8. Myers LK, Rosloniec EF, Cremer MA, Kang AH:
Collagen-induced arthritis, an animal model of autoim-
nunity, Life Sci 61:1861-1878, 1997.
9. Thornton S, Sowders D, Aronow B, Witte DP, Brunner HI,
Giannini EH, Hirsch R: DNA microarray analysis reveals
novel gene expression profiles in collagen-induced arthritis,
Clin Immunol 109:155-168, 2002.
10. Choy EF: Selective modulation of T-cell co-stimulation:
a novel mode of action for the treatment of rheumatoid
arthritis, Clin Exp Rheumatol 27:510-518, 2009.
11. Fournier C: Where do T cells stand in rheumatoid arthritis?
Joint Bone Spine 72:527-532, 2005.
12. Maddick-Nayak L, Allen PM: Initiation of an autoimmune re-
response: insights from a transgenic model of rheumatoid
arthritis, Immunol Res 32:5-13, 2005.
13. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T,
Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuji
S, Sakaguchi S: Altered thymic T-cell selection due to a mu-
tation of the ZAP-70 gene causes autoimmune arthritis in
mice, Nature 426:454-460, 2003.
14. Nandakumar KS, Svensson L, Holmdahl R: Collagen type
II-specific monoclonal antibody-induced arthritis in mice:
description of the disease and the influence of age, sex,
and genes, Am J Pathol 165:1827-1837, 2003.
15. Miceli MC, Barnes JR: The roles of CD4 and CD8 in T cell
activation, Semin Immunol 13:131-144, 1991.
16. Feldmann M, Brennan FM, Maini RN: Role of cytokines in
rheumatoid arthritis, Annu Rev Immunol 14:397-440, 1996.
17. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J,
Weisman L, Smolen J, Emery P, Harriman G, Feldmann
M, Lipsky P: Infliximab (chimeric anti-tumour necrosis fac-
tor alpha monoclonal antibody) versus placebo in rheuma-
toid arthritis patients receiving concomitant methotrexate:
a randomised phase III trial, ATTRACT Study Group,
Lancet 354:1925-1929, 1999.
18. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA,
Fleischmann RM, Weaver AL, Eitlinger RE, Cohen S,
Koopman WJ, Mohler K, Widmer MB, Bloch CM:
Description of the disease and the influence of age, sex,
and genes, Am J Pathol 165:1827-1837, 2003.
19. Miceli MC, Barnes JR: The roles of CD4 and CD8 in T cell
activation, Semin Immunol 13:131-144, 1991.
20. Booth G, Newham P, Barlow R, Raines S, Zheng B, Han
S: Gene expression profiles at different stages of colla-
gen-induced arthritis, Autoimmunity 41:512-521, 2008.
21. Calin A, Elwood J, Klouda PT: Destructive arthritis,
rheumatoid factor, and HLA-DR4, Susceptibility versus severity, a
case-control study. Arthritis Rheum 32:1221-1225, 1989.
22. Winchester R: The molecular basis of susceptibility to rhu-
matois arthritis, Adv Immunol 56:389-406, 1994.
23. Van Boxel JA, Paquet SA: Predominantly T-cell infiltrate in
rheumatoid synovial membranes, N Engl J Med 293:517-
520, 1975.
24. Knaus MC, Smets TJ, van Loon MJ, Breedveld FC,
Dijkmans BA, Tak PP: Differential effects of leflunomide and
methotrexate on cytokine production in rheumatoid
arthritis, Ann Rheum Dis 63:1056-1061, 2004.
25. Bertolot JM, Le Goff B, Mauguy Y: Thymic Hassall's cor-
puscles, regulatory T-cells, and rheumatoid arthritis, Semin
Arthritis Rheum 39:347-355, 2010.
26. Call ME, Wucherpfennig KW: Molecular mechanisms for
the assembly of the T cell receptor-CD3 complex, Mol
Immunol 40:1295-1305, 2004.
27. Kuhlman MS, Davis MM, Garcia KC: Deconstructing the form
and function of the TCR/CD3 complex, Immunity 24:133-
139, 2006.
28. Kiessling R, Kono K, Petersson M, Wasserman K:
Immunosuppression in human tumor-host interaction:
role of cytokines and alterations in signal-transducing
molecules, Springer Semin Immunopathol 18:227-242,
1996.
29. Finke JH, Zia AH, Stanley J, Longo DL, Mizoguchi H,
Tubbs BR, Willrout RH, O'Shea JJ, Koudoh S, Klein E,
Bukowski RM, Ochoa AC: Loss of T-cell receptor zeta chain
and p56lck in T cells infiltrating human renal cell carcino-
ma, Cancer Res 53:5613-5616, 1993.
30. Maurice MM, Lankee CE, Bezemer AC, Geertsema MF,
Tak PP, Breedveld FC, van Lier RA, Verweij CL: Defective
TCR-mediated signaling in synovial T cells in rheumatoid
arthritis, J Immunol 159:2573-2578, 1997.
31. Matsuda M, Ullgren AK, Lenkei R, Petersson M, Ochoa AC,
Lindblad S, Andersson P, Klarekslog L, Kiessling R:
Decreased expression of signal-transducing CD3 zeta
chains in T cells from the joints and peripheral blood of
rheumatoid arthritis patients, Scand J Immunol 47:254-262,
1998.
32. Trimble LA, Lieberman J: Circulating CD8 T lymphocytes
in human immunodeficiency virus-infected individuals have
impaired function and downmodulate CD3 zeta chain, the
signaling chain of the T-cell receptor complex, Blood 91:585-594,
1998.
33. Berg L, Rinnelid J, Klarekslog L, Bucht A: Down-regulation
of the T-cell receptor CD3 zeta chain in rheumatoid arthritis
(RA) and its influence on T cell responsiveness, Clin Exp
Immunol 120:174-182, 2000.
34. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V,
Joyeux I, D'Englihem CD, Lee R, Debue B, Fridman WH:
Variable expression of CD3-zeta chain in tumor-infiltrating
lymphocytes (TIL) derived from renal-cell carcinoma: rela-
tionship with TIL phenotype and function, Int J Cancer
35. de Vries JE, Yssel H, Spits H: Interplay between the TCR/CD3 complex and CD4 or CD8 in the activation of cytotoxic T lymphocytes. Immunol Rev 109:119-141, 1989.